KALA Valuation

KALA BIO Inc

Add to Watchlist

Advanced Chart

17.535

+0.065(0.372%)1D

Overview
Forecast
Valuation
Earnings

KALA Relative Valuation

KALA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KALA is overvalued; if below, it's undervalued.

Historical Valuation

KALA BIO Inc (KALA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.57. The fair price of KALA BIO Inc (KALA) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：17.47

Fair

-3.99

Trailing

Forward

0.00

EV/EBITDA

KALA BIO Inc. (KALA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.66. The thresholds are as follows: Strongly Undervalued below -3.33, Undervalued between -3.33 and -2.00, Fairly Valued between 0.67 and -2.00, Overvalued between 0.67 and 2.00, and Strongly Overvalued above 2.00. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-2.49

EV/EBIT

KALA BIO Inc. (KALA) has a current EV/EBIT of -2.49. The 5-year average EV/EBIT is -0.96. The thresholds are as follows: Strongly Undervalued below -3.30, Undervalued between -3.30 and -2.13, Fairly Valued between 0.21 and -2.13, Overvalued between 0.21 and 1.38, and Strongly Overvalued above 1.38. The current Forward EV/EBIT of -2.49 falls within the Undervalued range.

0.00

KALA BIO Inc. (KALA) has a current PS of 0.00. The 5-year average PS is 6.26. The thresholds are as follows: Strongly Undervalued below -13.18, Undervalued between -13.18 and -3.46, Fairly Valued between 15.99 and -3.46, Overvalued between 15.99 and 25.71, and Strongly Overvalued above 25.71. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-3.64

P/OCF

KALA BIO Inc. (KALA) has a current P/OCF of -3.64. The 5-year average P/OCF is -1.10. The thresholds are as follows: Strongly Undervalued below -4.62, Undervalued between -4.62 and -2.86, Fairly Valued between 0.65 and -2.86, Overvalued between 0.65 and 2.41, and Strongly Overvalued above 2.41. The current Forward P/OCF of -3.64 falls within the Undervalued range.

-3.15

P/FCF

KALA BIO Inc. (KALA) has a current P/FCF of -3.15. The 5-year average P/FCF is -1.24. The thresholds are as follows: Strongly Undervalued below -4.76, Undervalued between -4.76 and -3.00, Fairly Valued between 0.53 and -3.00, Overvalued between 0.53 and 2.29, and Strongly Overvalued above 2.29. The current Forward P/FCF of -3.15 falls within the Undervalued range.

KALA BIO Inc (KALA) has a current Price-to-Book (P/B) ratio of -38.17. Compared to its 3-year average P/B ratio of -0.18 , the current P/B ratio is approximately 21046.52% higher. Relative to its 5-year average P/B ratio of 0.50, the current P/B ratio is about -7728.57% higher. KALA BIO Inc (KALA) has a Forward Free Cash Flow (FCF) yield of approximately -20.26%. Compared to its 3-year average FCF yield of -219.62%, the current FCF yield is approximately -90.78% lower. Relative to its 5-year average FCF yield of -182.62% , the current FCF yield is about -88.91% lower.

-36.40

P/B

Median3y

-0.18

Median5y

0.50

-21.24

FCF Yield

Median3y

-219.62

Median5y

-182.62

Competitors Valuation Multiple

The average P/S ratio for KALA's competitors is 193.42, providing a benchmark for relative valuation. KALA BIO Inc Corp (KALA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Inovio Pharmaceuticals Inc

Avalo Therapeutics Inc

Loss

149.02M

TARA.O

Protara Therapeutics Inc

Loss

116.90M

PLX.A

Protalix Biotherapeutics Inc

2.00

16.21%

149.10M

Performance Decomposition

Market capitalization of KALA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of KALA in the past 1 year is driven by Unknown.